Palbociclib fails to benefit breast cancer subgroup, yielding lessons for future research

Adjuvant palbociclib combined with endocrine therapy failed to extend invasive DFS compared with endocrine therapy alone among patients with stage IIA hormone receptor-positive, HER2-negative breast cancer, according to study results.The findings, presented during an ASCO Plenary Series session, also showed the addition of the cyclin-dependent kinase (CDK)4/6 inhibitor did not improve other

Related Keywords

France ,Angela Demichele ,Fabrice Andre ,Mindy Valcarcel ,Calithera Biosciences ,Daiichi Sankyo ,Fabrice Andr ,Bydevin Mclaughlin ,Pfizer ,Astrazeneca ,Genentech ,Abramson Cancer Center At University Of Pennsylvania ,Novartis ,Eli Lilly Co ,Eli Lilly ,Abramson Cancer Center ,Gustave Roussy Cancer Campus ,